SCHOTT Pharma AG & Co. KGaA (FRA:1SXP)
Market Cap | 3.03B |
Revenue (ttm) | 975.68M |
Net Income (ttm) | 146.87M |
Shares Out | n/a |
EPS (ttm) | 0.97 |
PE Ratio | 20.61 |
Forward PE | 18.28 |
Dividend | 0.16 (0.80%) |
Ex-Dividend Date | Feb 5, 2025 |
Volume | 21,404 |
Average Volume | 55,251 |
Open | 20.20 |
Previous Close | 20.30 |
Day's Range | 20.10 - 20.35 |
52-Week Range | 18.50 - 32.74 |
Beta | n/a |
RSI | 38.76 |
Earnings Date | Dec 11, 2025 |
About FRA:1SXP
SCHOTT Pharma AG & Co. KGaA develops, manufactures, and sells drug containment solutions and delivery systems for injectable drugs for pharma, biotech, and life science industries worldwide. It offers syriQ, a glass syringe for vaccines; syriQ BioPure, a glass syringe for biologics; syriQ BioPure silicone-free, a prefillable and silicone-free glass syringe for biologics; SCHOTT TOPPAC, a polymer syringe; SCHOTT TOPPAC cosmetic, a polymer syringe for aesthetic treatments; SCHOTT TOPPAC freeze, a polymer syringe for deep-cold applications; SCHOTT... [Read more]
Financial Performance
In 2024, FRA:1SXP's revenue was 957.09 million, an increase of 6.51% compared to the previous year's 898.60 million. Earnings were 149.69 million, a decrease of -1.42%.
Financial StatementsNews

EQS-AFR: SCHOTT Pharma AG & Co. KGaA: Preliminary announcement of the publication of financial reports according to Articles 114, 115, 117 of the WpHG [the German Securities Act]
EQS Preliminary announcement financial reports: SCHOTT Pharma AG & Co. KGaA / Preliminary announcement on the disclosure of financial statements SCHOTT Pharma AG & Co. KGaA: Preliminary announcement o...

EQS-PVR: SCHOTT Pharma AG & Co. KGaA: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
EQS Voting Rights Announcement: SCHOTT Pharma AG & Co. KGaA SCHOTT Pharma AG & Co. KGaA: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective o...

EQS-AFR: SCHOTT Pharma AG & Co. KGaA: Preliminary announcement of the publication of financial reports according to Articles 114, 115, 117 of the WpHG [the German Securities Act]
EQS Preliminary announcement financial reports: SCHOTT Pharma AG & Co. KGaA / Preliminary announcement on the disclosure of financial statements SCHOTT Pharma AG & Co. KGaA: Preliminary announcement o...

EQS-AFR: SCHOTT Pharma AG & Co. KGaA: Preliminary announcement of the publication of quarterly reports and quarterly/interim statements
EQS Preliminary announcement financial reports: SCHOTT Pharma AG & Co. KGaA / Preliminary announcement on the disclosure of financial statements SCHOTT Pharma AG & Co. KGaA: Preliminary announcement o...

SCHOTT Pharma's Q3 Success: Strong Results Delivered!
SCHOTT Pharma's Q3 2025 results highlight a steady revenue climb and strategic innovations, setting the stage for future growth. With high-value solutions driving 60% of revenues, SCHOTT Pharma is on ...

EQS-News: SCHOTT Pharma delivers solid final third-quarter results
EQS-News: SCHOTT Pharma AG & Co. KGaA / Key word(s): Quarterly / Interim Statement/Quarter Results SCHOTT Pharma delivers solid final third-quarter results 12.08.2025 / 07:00 CET/CEST The issuer is so...

SCHOTT Pharma Unveils Q3 2025 Results & FY Guidance
SCHOTT Pharma's Q3 2025 results showcase a remarkable financial performance, driven by strategic growth in High Value Solutions. Jetzt den vollständigen Artikel lesen

EQS-News: SCHOTT Pharma reports preliminary results for Q3 2025 and specifies FY 2025 guidance
EQS-News: SCHOTT Pharma AG & Co. KGaA / Key word(s): Forecast/Preliminary Results SCHOTT Pharma reports preliminary results for Q3 2025 and specifies FY 2025 guidance 05.08.2025 / 09:55 CET/CEST The i...

SCHOTT Pharma Targets 2025 Revenue & EBITDA Growth
In a strategic move towards transparency, SCHOTT Pharma AG & Co. KGaA unveils its ambitious financial forecast for FY 2025, highlighting a promising trajectory in revenue and profitability. Jetzt den ...

EQS-Adhoc: SCHOTT Pharma AG & Co. KGaA: SCHOTT Pharma specifies FY 2025 guidance for revenue growth and EBITDA margin
EQS-Ad-hoc: SCHOTT Pharma AG & Co. KGaA / Key word(s): Forecast/Change in Forecast SCHOTT Pharma AG & Co. KGaA: SCHOTT Pharma specifies FY 2025 guidance for revenue growth and EBITDA margin 05-Aug-202...

EQS-News: SCHOTT Pharma Supervisory Board extends contract of CEO Andreas Reisse and appoints Reinhard Mayer as new CFO
EQS-News: SCHOTT Pharma AG & Co. KGaA / Key word(s): Personnel/Contract SCHOTT Pharma Supervisory Board extends contract of CEO Andreas Reisse and appoints Reinhard Mayer as new CFO 11.06.2025 / 08:50...

CTP builds 18,000 sqm Serbian facility for SCHOTT Pharma as it expands global manufacturing network
Regulatory News: CTP, Europe's largest listed developer, owner, and manager of industrial and logistics properties by gross lettable area (GLA), has developed a new 18,000 sqm build-to-suit production...

SCHOTT Pharma Achieves Impressive Q2 Results in Fiscal 2025
SCHOTT Pharma's Q2 2025 results showcase robust growth and innovation, with an 8% revenue surge and strategic product advancements, despite global economic challenges. Jetzt den vollständigen Artikel ...

EQS-News: SCHOTT Pharma delivers strong second quarter of fiscal year 2025
EQS-News: SCHOTT Pharma AG & Co. KGaA / Key word(s): Half Year Report/Half Year Results SCHOTT Pharma delivers strong second quarter of fiscal year 2025 15.05.2025 / 07:00 CET/CEST The issuer is solel...

EQS-News: SCHOTT Pharma and Serum Institute of India welcome new partner to Joint Venture in India; TPG makes strategic investment in SCHOTT Poonawalla
EQS-News: SCHOTT Pharma AG & Co. KGaA / Key word(s): Investment SCHOTT Pharma and Serum Institute of India welcome new partner to Joint Venture in India; TPG makes strategic investment in SCHOTT Poona...

SCHOTT Pharma Exceeds Market Expectations in Q2 2025
SCHOTT Pharma's Q2 2025 results reveal a 10% revenue growth, surpassing market forecasts and showcasing financial strength with a 28.6% EBITDA margin. More details are expected on May 15, 2025. Jetzt ...

EQS-Adhoc: SCHOTT Pharma AG & Co. KGaA: SCHOTT Pharma: Preliminary Q2 2025 figures exceed capital market expectations
EQS-Ad-hoc: SCHOTT Pharma AG & Co. KGaA / Key word(s): Quarterly / Interim Statement/Quarter Results SCHOTT Pharma AG & Co. KGaA: SCHOTT Pharma: Preliminary Q2 2025 figures exceed capital market expec...

EQS-News: Next expansion milestone achieved: SCHOTT Pharma opens production facility in Serbia to strengthen competitiveness in Europe
EQS-News: SCHOTT Pharma AG & Co. KGaA / Key word(s): Expansion Next expansion milestone achieved: SCHOTT Pharma opens production facility in Serbia to strengthen competitiveness in Europe 10.04.2025 /...

EQS-AFR: SCHOTT Pharma AG & Co. KGaA: Preliminary announcement of the publication of financial reports according to Articles 114, 115, 117 of the WpHG [the German Securities Act]
EQS Preliminary announcement financial reports: SCHOTT Pharma AG & Co. KGaA / Preliminary announcement on the disclosure of financial statements SCHOTT Pharma AG & Co. KGaA: Preliminary announcement o...

SCHOTT Pharma's Strong Q1: Confirms 2023 Outlook
SCHOTT Pharma navigates a dynamic market landscape with strategic innovation and steady growth, despite a slight dip in Q1 2025 revenues. Jetzt den vollständigen Artikel lesen

EQS-News: SCHOTT Pharma records good start into fiscal year and confirms full year outlook
EQS-News: SCHOTT Pharma AG & Co. KGaA / Key word(s): Quarterly / Interim Statement/Quarter Results SCHOTT Pharma records good start into fiscal year and confirms full year outlook 13.02.2025 / 07:00 C...
SCHOTT Pharma AG & Co. KGaA goes ex dividend tomorrow

EQS-News: SCHOTT Pharma with successful Annual General Meeting: Shareholders approve all agenda items
EQS-News: SCHOTT Pharma AG & Co. KGaA / Key word(s): AGM/EGM SCHOTT Pharma with successful Annual General Meeting: Shareholders approve all agenda items 04.02.2025 / 18:22 CET/CEST The issuer is solel...

Schott Pharma carefully observing impact of Trump 2.0 on industry, says CEO
Andreas Reisse, CEO of Schott Pharma, discusses the German pharmaceutical supplier's fourth-quarter earnings.

SCHOTT Pharma Achieves Record Growth and Margins After Strong Year-End
SCHOTT Pharma has marked a milestone year in FY 2024, boasting a 12% revenue surge and a record EBITDA margin of 27.8%. With innovation and strategic alliances, the company is poised for continued suc...